Horizon And Arrowhead To Develop RNAi Therapeutic For Gout

Target Is Xanthine Dehydrogenase, Primary Source Of Serum Uric Acid

 
• By Sten Stovall
  
Gout Pact Will Give Arrowhead $40m upfront • Source: Alamy

More from Immunological

More from Therapy Areas